Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. The company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company's main capabilities include clinical development, vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. The company is conducting a clinical trial for its gene therapy candidate ADVM-022, AAV.7m8-aflibercept, for the treatment of wet age-related macular degeneration.

Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, severe skin disease, and cancer. The company is using its galectin-3 inhibitor, GR-MD-02 to treat liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The company has established several collaborative scientific discovery programs in carbohydrate chemistry and characterization. The company also has established through its subsidiary, Galectin Sciences LLC, a discovery program for the targeted development of small molecules (generally, non-carbohydrate) that bind galectin proteins.

Landec designs, develops, manufactures and sells health and wellness products for food and biomaterials markets. The company operates its business in two reportable business segments: Curation Foods, and Lifecore. The Curation Foods business is comprised of Curation Foods' packaged vegetables business sold primarily under the Eat Smart? brand, O Olive Oil & Vinegar? olive oils and wine vinegars, and Yucatan? and Cabo Fresh? guacamole and avocado food products. Lifecore is involved in the manufactures of pharmaceutical-grade sodium hyaluronate in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.